Oxytocin as an adolescent treatment for methamphetamine addiction after early life stress in male and female rats

• Published in: Neuropsychopharmacology (New York, N.Y.) Vol. 47; no. 8; pp. 1561 - 1573
• Main Authors: Baracz, Sarah J, Robinson, Katherine J, Wright, Amanda L, Turner, Anita J, McGregor, Iain S, Cornish, Jennifer L, Everett, Nicholas A
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.07.2022; Springer International Publishing
• Subjects: Addictions; Amphetamine-Related Disorders - drug therapy; Animals; Anxiety; Corticosterone; Corticosterone - analysis; Corticotropin-releasing hormone; Extinction, Psychological; Female; Hypothalamus; Immunofluorescence; Male; Males; Maternal Deprivation; Methamphetamine; Methamphetamine - adverse effects; Oxytocin; Oxytocin - therapeutic use; Psychopathology; Rats; Rats, Long-Evans; Reinstatement; Rodents; Self-administration; Stress; Stress, Psychological - drug therapy; Yohimbine; Yohimbine - pharmacology
• ISSN: 0893-133X; 1740-634X
• DOI: 10.1038/s41386-022-01336-y

Early life stress (ELS) is associated with perturbed neural development and augmented vulnerability to mental health disorders, including addiction. How ELS changes the brain to increase addiction risk is poorly understood, and there are no therapies which target this ELS-induced vulnerability. ELS disrupts the oxytocin system, which can modulate addiction susceptibility, suggesting that targeting the oxytocin system may be therapeutic in this ELS-addiction comorbidity. Therefore, we determined whether adolescent oxytocin treatment after ELS could: (1) reduce vulnerability to anxiety, social deficits, and methamphetamine-taking and reinstatement; and (2) restore hypothalamic oxytocin and corticotropin-releasing factor expressing neurons and peripheral oxytocin and corticosterone levels. Long Evans pups underwent maternal separation (MS) for either 15 min or 360 min on postnatal days (PND) 1-21. During adolescence (PNDs 28-42), rats received a daily injection of either oxytocin or saline. In Experiment 1, adult rats were assessed using the elevated plus-maze, social interaction procedure, and methamphetamine self-administration procedure, including extinction, and cue-, methamphetamine- and yohimbine-induced reinstatement. In Experiment 2, plasma for enzyme immunoassays and brain tissue for immunofluorescence were collected from adult rats after acute stress exposure. Adolescent oxytocin treatment ameliorated ELS-induced anxiety and reduced methamphetamine- and yohimbine-induced reinstatement in both sexes, and suppressed methamphetamine intake and facilitated extinction in males only. Additionally, adolescent oxytocin treatment after ELS restored oxytocin-immunoreactive cells and stress-induced oxytocin levels in males, and attenuated stress-induced corticosterone levels in both sexes. Adolescent oxytocin treatment reverses some of the ELS effects on later-life psychopathology and vulnerability to addiction.